Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics announced new data on ATA188 for progressive multiple sclerosis (MS), highlighting a two-year open-label extension (OLE) study. Significant findings include improved magnetization transfer ratio (MTR) indicative of possible remyelination and sustained disability improvement in patients over 33 months. Of 24 patients evaluated, 18 continued in the OLE, with 9 meeting sustained disability improvement criteria. The data presentation is scheduled for October 13, 2021, at the ECTRIMS Congress, showcasing Atara's commitment to developing innovative T-cell therapies for MS.

Atara Biotherapeutics (NASDAQ: ATRA) announced that the European Medicines Agency's CHMP granted accelerated assessment for its lead product candidate, tabelecleucel (tab-cel), aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Currently, there are no approved therapies for this life-threatening condition. The Marketing Authorization Application (MAA) is expected to be submitted in November 2021, with a potential approval decision anticipated in the second half of 2022.

Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 74,055 restricted stock units and stock options for 59,869 shares to newly hired employees. These awards, part of Atara's 2018 Inducement Plan, were approved by the Compensation Committee. The RSUs vest over four years, while the stock options have a ten-year term with an exercise price of $15.69 per share. This initiative aims to attract and retain talent in the competitive biotherapeutics market, adhering to Nasdaq rules.

Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in a panel discussion at the Citi 16th Annual BioPharma Virtual Conference on September 9, 2021, at 7:40 a.m. PDT. The discussion will focus on the current landscape of cell therapy, including autologous and allogeneic CAR-T and CAR-NK therapies. Interested parties can access a live webcast through Atara's Investor Events and Presentations webpage, with an archived replay available for 30 days. Atara specializes in developing therapies for cancer and autoimmune diseases using its EBV T-cell platform.

Atara Biotherapeutics (ATRA) reported its Q2 2021 financial results, highlighting significant regulatory progress for tab-cel® and anticipated approvals in 2022. The company expects to submit a Biologics License Application for tab-cel® by Q1 2022 and aims for EU Marketing Authorization Application submission in November 2021. Financially, Atara recorded a net loss of $83.8 million, or $0.91 per share, with cash reserves at $373.4 million, projected to fund operations into 2023. Increased R&D expenses were noted, reflecting investments in pipeline programs.

Atara Biotherapeutics (Nasdaq: ATRA) announces the appointment of Ameet Mallik to its Board of Directors. Mr. Mallik, an expert in biotechnology with over 25 years of experience, has a successful history of bringing oncology therapeutics to market. His leadership is expected to enhance Atara's efforts to commercialize its lead product, tab-cel®, anticipated for approval in 2022. Mallik's expertise spans commercial operations at Novartis and Rafael Holdings, positioning him to drive Atara's mission of transforming the lives of patients with serious diseases.

Atara Biotherapeutics (Nasdaq:ATRA) announced the grant of 110,626 restricted stock units and stock options for 69,744 shares to newly hired employees. These awards were approved by the Compensation Committee under the 2018 Inducement Plan, effective August 2, 2021. The restricted stock units will vest over four years, with the first 25% vesting after one year. The stock options also vest over four years, starting with 25% after the first anniversary. This action complies with Nasdaq Listing Rule 5635(c)(4).

Atara Biotherapeutics announced it will release its second quarter 2021 financial results post-market on August 9, 2021. Following the release, a live conference call will be held at 4:30 p.m. EDT to discuss financial results and provide corporate updates. Participants can join by calling 877-407-8291 for domestic callers or 201-689-8345 for international. The company aims to provide transformative therapies using its EBV T-cell platform to address serious diseases.

Atara Biotherapeutics (Nasdaq: ATRA) has granted 124,580 restricted stock units and options to purchase 99,585 shares to newly hired employees as part of its 2018 Inducement Plan. The stock options have a ten-year term with an exercise price of $16.05 per share, aligning with the company's closing stock price on July 1, 2021. The awards support Atara’s strategy to attract talent in the competitive T-cell immunotherapy field, aimed at developing therapies for cancer and autoimmune diseases.